A Randomized, Placebo Controlled Trial Of Zoledronic Acid For The Prevention Of Bone Loss In Premenopausal Women With Early Stage Breast Cancer

Trial Profile

A Randomized, Placebo Controlled Trial Of Zoledronic Acid For The Prevention Of Bone Loss In Premenopausal Women With Early Stage Breast Cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Jan 2014

At a glance

  • Drugs Zoledronic acid (Primary)
  • Indications Osteoporosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 10 Jan 2014 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov record.
    • 18 Dec 2009 Secondary analysis published in the the Journal of Clinical Endocrinology and Metabolism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top